<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[SCYNEXIS, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=21755></link><description><![CDATA[SCYNEXIS, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 19:44:30 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2014/02/12_740813719_20140225202414_1285096619.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[SCYNEXIS Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Antifungal Agent SCY-078 for Oral Use]]></title><link>https://www.newswire.co.kr/newsRead.php?no=738912</link><description><![CDATA[RESEARCH TRIANGLE PARK, N.C.--(Business Wire/Korea Newswire)--Drug discovery and development company SCYNEXIS, Inc., today announced that the Food and Drug Administration (FDA) designated SCY-078 as a Qualified Infectious Disease Product (QIDP) for oral use for the indications of invasive Candidiasis, including Candidemia, and invasive Aspergillosis. The QIDP designation, provided under the 2012 U.S. Gener...]]></description><pubDate>Tue, 25 Feb 2014 20:50:00 +0900</pubDate></item><item><title><![CDATA[시넥시스 경구용 항진균제 SCY-078, FDA로부터 QIDP선정]]></title><link>https://www.newswire.co.kr/newsRead.php?no=738913</link><description><![CDATA[리서치 트라이앵글 파크, 노스 캐롤라이나--(Business Wire/뉴스와이어)--신약개발기업인 시넥시스(SCYNEXIS, Inc.)는 오늘 미국 식품의약국(Food and Drug Administration, FDA)가 칸디다성패혈증(Candidemia)과 같은 침습성 칸디다증(Candidiasis)과 침습성 아스페르길루스증(Aspergillosis) 등의 조짐에 사용하는 경구용 약으로 SCY-078를 감염성질환 제품인증(Qualified Infectious Disease Product, QIDP) 선정했다고 발표했다. 2012년 미국 ...]]></description><pubDate>Tue, 25 Feb 2014 20:50:00 +0900</pubDate></item></channel></rss>